日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Sino Biopharm targets 30 innovative products by 2027

By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2025-03-21 14:23
Share
Share - WeChat

Sino Biopharmaceutical Limited, or Sino Biopharm, expects to have approximately five innovative products approved in China each year, bringing the total of its innovative products to at least 30 by 2027, the company announced at a conference on Thursday, where it released its 2024 annual results.

Such continuous innovation efforts demonstrate the company's commitment to meeting patients' clinical needs and contributing to the Healthy China initiative, said Theresa Tse, chairwoman of Sino Biopharm.

The report showed that the Hong Kong-listed company's dedication to innovation has paid off, with its 2024 operating revenue and net profit both achieving double-digit growth. The company reported a total revenue of 28.87 billion yuan ($3.98 billion), representing a 10.2 percent year-on-year increase, while adjusted net profit attributable to shareholders reached 3.46 billion yuan, a 33.5 percent surge.

For the first time, the company also achieved over 10-billion-yuan revenue from its innovative products last year, reaching 12.06 billion yuan, a 21.9 percent year-on-year growth, which accounts for 41.8 percent of the company's total revenue.

"Our relentless focus on innovation over the past decade has led to the establishment of innovative research and development platforms for dual antibodies and ADC (antibody-drug conjugate) drugs among others, resulting in a steady stream of innovative products," said Tse.

The number of innovative products by Sino Biopharm increased from three in 2018 to 17 by the end of 2024, according to the report. Last year alone, the company saw four first-class innovative medicines approved for market, making it the pharmaceutical enterprise with the largest number of such approvals in the year.

Looking ahead, Sino Biopharm anticipates the launch of several blockbuster products for treatment of lung cancer, chronic obstructive pulmonary disease, breast cancer, and others within the next three years.

The company also said that it has strategically positioned itself in the realm of artificial intelligence through collaborations, investments and localized applications. It plans to intensify its investments in AI, expanding its application across R&D, production, sales and functional management to propel corporate development and lead industry innovation upgrades.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 6080yy精品一区二区三区 | 亚洲欧美在线免费观看 | 日韩免费一区二区 | 亚洲国产精品视频 | 色综合加勒比 | 奇米 影音先锋 | 奇米影视第七色 | 午夜你懂得 | 99精品国产一区二区青青牛奶 | 免费一级毛片 | 一区二区三区视频免费观看 | 69国产成人精品午夜福中文 | 99亚洲视频| 成人爽a毛片在线视频网站 婷婷色在线观看 | 国产精品色在线网站 | 免费在线一区二区 | 久久久国产一区二区三区 | 欧美激情午夜 | 欧美高潮 | 亚洲欧洲中文日韩久久AV乱码 | 日韩在线观看中文字幕 | 97一本大道波多野吉衣 | 久久精品视频5 | 久久人人爽人人爽 | 免费看的久久久久 | 亚洲国产片高清在线观看 | 欧美a级毛毛片免费视频试播 | 日韩成人av在线 | 人人看人人做 | 国产精品久久99 | 国产99久久精品 | 日韩欧美国产视频 | 69av.com| 99久久亚洲精品日本无码 | 久九九精品免费视频 | 欧美一区二区免费 | 亚洲欧美国产精品久久久久久久 | 欧美中文在线观看 | 亚洲欧美激情另类 | 伊人成人在线观看 | 免费一区二区三区 |